foxo4-dri dosage chart Chart: 1mg Senolytic Protocol (2026) Frontiers | FOXO4-DRI regulates endothelial

What is missing There is no published human pharmacokinetic study of subcutaneous AOD-9604, no published human topical or intranasal exposure data, no Phase 3 efficacy trial, no long-term safety data beyond 24 weeks, and no published human cartilage or joint outcome data

BPC-157 is predominately indicated for people who need joint and/or digestive (upper/lower) support

While the main reason for BPC-157s popularity is its potential for speeding up recovery, there is no evidence that the peptide can exert any of these effects in humans

Patients often notice improved vision stability, increased comfort, and reduced burning, redness, dryness, and other bothersome symptoms within days

In my practice, I constantly encounter patients who feel theyve hit a wall